A comparative study of Sitagliptin- Glimepiride combinational therapy and Glimepiride monotherapy on the patients with diabetes mellitus after pancreatic biliary diseases including malignant disorders related subtotal pancreatectomy

A comparative study of Sitagliptin- Glimepiride combinational therapy and Glimepiride monotherapy on the patients with diabetes mellitus after pancreatic biliary diseases including malignant disorders related subtotal pancreatectomy - A comparative study of Sitagliptin- Glimepiride combinational therapy and Glimepiride monotherapy on the patients with diabetes mellitus after subtotal pancreatectomy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004645

Enrollment

Registered

2010-12-02

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus after pancreatic biliary diseases including malignant disorders related subtotal pancreatectomy

Interventions

50 mg of Sitagliptin monotherapy once daily on diabetes mellitus after subtotal pancreatectomy. If necessary, Glimepiride therapy will be combined 0.5 mg of Glimepiride monotherapy once daily on diabe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (a) Patients were underwent subtotal pancreatectomy. (b) Patients are outpatients or inpatients (c) Patients need anti-diabetic agents after subtotal pancreatectomy. (d) Patients with a therapy of diabetes mellitus before subtotal pancreatectomy.

Exclusion criteria

Exclusion criteria: (a) Patients with a history of total pancreatectomy. (b) Patients with insulin-dependent diabetes mellitus. (c) Patients with a history of severe cardiovascular or cerebrovascular disease or renal failure. (c) Patients have contraindication of Sitagliptin, Glimepiride and glucagon. (d) Patients with severe liver damage. (e) Patients are pregnant or patients breast-feeding, potentially pregnant. (f) Patients who are diagnosed to be ineligible by the investigator.

Design outcomes

Primary

Measure	Time frame
Delta C-peptide in glucagon injection. (delta C-peptide = max C-peptide &#8211; base C-peptide) Comparison the mean of delta C-peptide from before treatment to the end of the study between Sitagliptin- Glimepiride combinational therapy and Glimepiride monotherapy	—

Countries

Japan

Contacts

Public ContactTsuguka Shiwa

Hiroshima University Hospital Department of Endocrinology and Diabetes mellitus

tsuguka@hiroshima-u.ac.jp082-257-5198

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026